866-997-4948(US-Canada Toll Free)

Metastatic Colorectal Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : May 2016

Category :

Cancer

No. of Pages : 718 Pages

Metastatic Colorectal Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H1 2016, provides an overview of the Metastatic Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
- The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Metastatic Colorectal Cancer Overview 8
Therapeutics Development 9
Metastatic Colorectal Cancer - Therapeutics under Development by Companies 11
Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Colorectal Cancer - Pipeline Products Glance 18
Metastatic Colorectal Cancer - Products under Development by Companies 22
Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 30
Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 31
Metastatic Colorectal Cancer - Therapeutics Assessment 115
Drug Profiles 140
Metastatic Colorectal Cancer - Recent Pipeline Updates 436
Metastatic Colorectal Cancer - Dormant Projects 681
Metastatic Colorectal Cancer - Discontinued Products 690
Metastatic Colorectal Cancer - Product Development Milestones 693
Appendix 702

List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H1 2016 24
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016 25
Number of Products under Development by Companies, H1 2016 26
Number of Products under Development by Companies, H1 2016 (Contd..1) 27
Number of Products under Development by Companies, H1 2016 (Contd..2) 28
Number of Products under Development by Companies, H1 2016 (Contd..3) 29
Number of Products under Development by Companies, H1 2016 (Contd..4) 30
Number of Products under Development by Companies, H1 2016 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H1 2016 32
Comparative Analysis by Late Stage Development, H1 2016 33
Comparative Analysis by Clinical Stage Development, H1 2016 34
Comparative Analysis by Early Stage Development, H1 2016 35
Comparative Analysis by Unknown Stage Development, H1 2016 36
Products under Development by Companies, H1 2016 37
Products under Development by Companies, H1 2016 (Contd..1) 38
Products under Development by Companies, H1 2016 (Contd..2) 39
Products under Development by Companies, H1 2016 (Contd..3) 40
Products under Development by Companies, H1 2016 (Contd..4) 41
Products under Development by Companies, H1 2016 (Contd..5) 42
Products under Development by Companies, H1 2016 (Contd..6) 43
Products under Development by Companies, H1 2016 (Contd..7) 44
Products under Investigation by Universities/Institutes, H1 2016 45
Metastatic Colorectal Cancer - Pipeline by AB Science SA, H1 2016 46
Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016 47
Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 48
Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 49
Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016 50
Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2016 51
Metastatic Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016 52
Metastatic Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016 53
Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016 54
Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 55
Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016 56
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 57
Metastatic Colorectal Cancer - Pipeline by Baxalta Incorporated, H1 2016 58
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2016 59
Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2016 60
Metastatic Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016 61
Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H1 2016 62
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 63
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 64
Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016 65
Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016 66
Metastatic Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016 67
Metastatic Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016 68
Metastatic Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 69
Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 70
Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016 71
Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 72
Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016 73
Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016 74
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2016 75
Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H1 2016 76
Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H1 2016 77
Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2016 78
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 79
Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 80
Metastatic Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H1 2016 81
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2016 82
Metastatic Colorectal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2016 83
Metastatic Colorectal Cancer - Pipeline by Hetero Drugs Limited, H1 2016 84
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 85
Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H1 2016 86
Metastatic Colorectal Cancer - Pipeline by Immatics Biotechnologies GmbH, H1 2016 87
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016 88
Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2016 89
Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016 90
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 91
Metastatic Colorectal Cancer - Pipeline by Mabion SA, H1 2016 92
Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H1 2016 93
Metastatic Colorectal Cancer - Pipeline by mAbxience S.A., H1 2016 94
Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2016 95
Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H1 2016 96
Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2016 97
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2016 98
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 99
Metastatic Colorectal Cancer - Pipeline by Merus B.V., H1 2016 100
Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 101
Metastatic Colorectal Cancer - Pipeline by Mologen AG, H1 2016 102
Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2016 103
Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 104
Metastatic Colorectal Cancer - Pipeline by Natco Pharma Limited, H1 2016 105
Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2016 106
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 107
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2016 108
Metastatic Colorectal Cancer - Pipeline by OBI Pharma, Inc., H1 2016 109
Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2016 110
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 111
Metastatic Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 112
Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2016 113
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2016 114
Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H1 2016 115
Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 116
Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2016 117
Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 118
Metastatic Colorectal Cancer - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016 119
Metastatic Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 120
Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016 121
Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H1 2016 122
Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 123
Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 124
Metastatic Colorectal Cancer - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 125
Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016 126
Metastatic Colorectal Cancer - Pipeline by Tocagen Inc., H1 2016 127
Metastatic Colorectal Cancer - Pipeline by Vaximm AG, H1 2016 128
Metastatic Colorectal Cancer - Pipeline by XBiotech USA, Inc., H1 2016 129
Assessment by Monotherapy Products, H1 2016 130
Assessment by Combination Products, H1 2016 131
Number of Products by Stage and Target, H1 2016 133
Number of Products by Stage and Mechanism of Action, H1 2016 144
Number of Products by Stage and Route of Administration, H1 2016 152
Number of Products by Stage and Molecule Type, H1 2016 154
Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 451
Metastatic Colorectal Cancer - Dormant Projects, H1 2016 697
Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H1 2016 698
Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H1 2016 699
Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H1 2016 700
Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H1 2016 701
Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H1 2016 702
Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H1 2016 703
Metastatic Colorectal Cancer - Dormant Projects (Contd..7), H1 2016 704
Metastatic Colorectal Cancer - Dormant Projects (Contd..8), H1 2016 705
Metastatic Colorectal Cancer - Discontinued Products, H1 2016 706
Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H1 2016 707
Metastatic Colorectal Cancer - Discontinued Products (Contd..2), H1 2016 708

List of Figures
Number of Products under Development for Metastatic Colorectal Cancer, H1 2016 24
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016 25
Number of Products under Development by Companies, H1 2016 26
Number of Products under Investigation by Universities/Institutes, H1 2016 32
Comparative Analysis by Late Stage Development, H1 2016 33
Comparative Analysis by Clinical Stage Development, H1 2016 34
Comparative Analysis by Early Stage Products, H1 2016 35
Assessment by Monotherapy Products, H1 2016 130
Assessment by Combination Products, H1 2016 131
Number of Products by Top 10 Targets, H1 2016 132
Number of Products by Stage and Top 10 Targets, H1 2016 132
Number of Products by Top 10 Mechanism of Actions, H1 2016 143
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 143
Number of Products by Top 10 Routes of Administration, H1 2016 151
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 151
Number of Products by Top 10 Molecule Types, H1 2016 153
Number of Products by Stage and Top 10 Molecule Types, H1 2016 153

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *